Fairvalue-Calculator Fairvalue-Calculator
EN DE

Concord Biotech Limited (CONCORDBIO) Fair Value & Analysis

Healthcare · IN · Market cap ₹134B

Price₹1,286
Fair Value₹477.10
Upside-62.9%
Quality97/100
Evidence: High Range ₹294.18 – ₹596.11

Fair value as of: Jun 29, 2026

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

Concord Biotech Limited (CONCORDBIO) currently trades at ₹1,286, while our model-based Fair Value estimate is ₹477.10 — implying the stock looks roughly 62.9% overvalued today. We read business quality at 97/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin, doxorubicin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment. In addition, the company provides mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, and nystatin for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. Further, it develops daptom…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is Concord Biotech Limited (CONCORDBIO) undervalued?
As of Jun 29, 2026, our model estimates a fair value of ₹477.10 versus a price of ₹1,286 — about −63% (overvalued). Model-based estimate, not financial advice.
What is the fair value of CONCORDBIO?
Our 21-model fair value for Concord Biotech Limited is ₹477.10 (as of Jun 29, 2026), built from audited fundamentals. The current price is ₹1,286.
What is the quality score of CONCORDBIO?
Concord Biotech Limited has a Quality Score of 97/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.